Effective orally available drug combination of OR2100 and venetoclax in acute myeloid leukemia

被引：0
|
作者：
Ureshino, Hiroshi [1 ,2 ,3 ]
Watanabe, Tatsuro [2 ]
Kimura, Shinya [1 ,2 ]
机构：
[1] Saga Univ, Dept Hematol & Oncol, Saga, Japan
[2] Saga Univ, Dept Drug Discovery & Biomed Sci, Saga, Japan
[3] Hiroshima Univ, Res Inst Radiat Biol & Med, Higashihiroshima, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-1006
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [31] Decitabine in Combination with Venetoclax in Six Elderly Patients with Acute Myeloid Leukemia (AML)
    Rios, Adan
    Kanaan, Zeyad
    Nghia Nguyen
    Rekoff, Gregg
    Chen, Lei
    Wahed, Amer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S211 - S211
  • [32] Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
    Zhai, Yifan
    Tang, Qiuqiong
    Fang, Douglas D.
    Deng, Jing
    Zhang, Kaixiang
    Wang, Qixin
    Yin, Yan
    Fu, Chengcheng
    Xue, Sheng -Li
    Li, Na
    Zhou, Feng
    Yang, Dajun
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 183 - 196
  • [33] Combined venetoclax and alvocidib in acute myeloid leukemia
    Bogenberger, James
    Whatcott, Clifford
    Hansen, Nanna
    Delman, Devora
    Shi, Chang-Xin
    Kim, Wontak
    Haws, Hillary
    Soh, Katherine
    Lee, Ye Sol
    Peterson, Peter
    Siddiqui-Jain, Adam
    Weitman, Steven
    Stewart, Keith
    Bearss, David
    Mesa, Ruben
    Warner, Steven
    Tibes, Raoul
    ONCOTARGET, 2017, 8 (63): : 107206 - 107222
  • [34] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [35] Prescription patterns of venetoclax in acute myeloid leukemia
    Ucciero, Andrealuna
    Traversa, Giuseppe
    Pisterna, Alessia
    Cardinali, Valeria
    Sciabolacci, Sofia
    Poloni, Antonella
    Capelli, Debora
    Gaidano, Gianluca
    Patriarca, Andrea
    Lunghi, Monia
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
  • [36] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary
    LEUKEMIA RESEARCH, 2020, 90
  • [37] Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm
    Tremblay, Douglas
    Feld, Jonathan
    Dougherty, Mikaela
    Czaplinska, Tina
    Sanchez, Gillian
    Kremyanskaya, Marina
    Bar-Natan, Michal
    Shih, Alan H.
    Keyzner, Alla
    Mascarenhas, John
    LEUKEMIA RESEARCH, 2020, 98
  • [38] Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.
    Jonas, Brian Andrew
    Dinardo, Courtney Denton
    Pratz, Keith
    Wei, Andrew
    Hong, Wan-Jen
    Chyla, Brenda
    Duan, Yinghui
    Potluri, Jalaja
    Werner, Michael
    Pollyea, Daniel Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis
    Edahiro, Taro
    Ureshino, Hiroshi
    Chishaki, Ren
    Fujino, Keita
    Mino, Tatsuji
    Yoshida, Tetsumi
    Fukushima, Noriyasu
    Ichinohe, Tatsuo
    LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3511 - 3512
  • [40] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
12345